COAST Development Group's international consensus guidelines for the treatment of canine osteoarthritis.

This report describes consensus guidelines and recommendations for the treatment of canine osteoarthritis (OA) according to the "Canine OsteoArthritis Staging Tool excluding radiography" (COASTeR) stage of OA, by the COAST Development Group. The recommendations are based on evidence-based medicine and clinical experience and are proposed with international relevance in mind. The aim is to provide veterinarians with a practical reference to consolidated information and to support the development of patient-specific OA management protocols and informed treatment choices based on the stage of OA.

Informations de copyright

Copyright © 2023 Cachon, Frykman, Innes, Lascelles, Okumura, Sousa, Staffieri, Steagall and Van Ryssen.

Déclaration de conflit d'intérêts

In the past 5 years: TC has provided consultancy or advisor services to Elanco, TVM, and Arthrex and has received speaker honoraria from Elanco, Arthrex, and Zoetis. OF has provided consultancy services or received speaker honoraria from Orion Pharma Animal Health, Elanco, Boehringer Ingelheim, and Hill's Pet Nutrition. JI has provided consultancy services to Elanco, Zoetis, UK Vet Partners, Altius, Stonehaven Consulting, Cemplicity, and Fusion Implants. He is also the developer of the Liverpool Osteoarthritis in Dogs (LOAD) client-reported outcomes measure which is licensed to Elanco by the University of Liverpool. BDXL has provided consultancy services, or engaged in paid continuing education, for Assisi, Avista, Anterra, Boehringer Ingelheim, Centrexion, Chromocell, Elanco, Holistapet, Regeneron, Sorrento, Stonehaven, Vetoquinol, Vetfolio, VetzPetz, VetStem, Virbac, and Zoetis; and has received research funding from Boehringer Ingelheim, Centrexion, Ceva, Chilean Government (National Commission for Scientific and Technological Research), Elanco, Invetx, Morris Animal Foundation, Mayday Fund, NIH, Private Client Donations, Tulane University, Vetana, Virbac, Winn Feline Foundation, and Zoetis. MO has provided consultancy services or received speaker honoraria from Bayer, Boehringer Ingelheim, DS Pharma, Elanco, JRA, OJI Holdings, OJI Pharma, University of Brawijaya, and Zoetis, and has received research funding from DS Pharma, JRA, JSPS, OJI holdings, OJI Pharma, and ONO Pharmaceutical. PS has provided consultancy services to Elanco and Ecuphar/Animal Care. FS has acted as a key opinion leader and received a speaker honorarium from Elanco, Vetoquinol, and Orion. PVS has provided consultancy services to Boehringer Ingelheim, Dechra Pharmaceuticals, Elanco, and Zoetis, acted as a key opinion leader to Boehringer Ingelheim, Dechra Pharmaceuticals, Elanco, Vetoquinol, and Zoetis, and received speaker honoraria from Boehringer Ingelheim, Dechra, Elanco, and Zoetis. BV has performed consultancy services and received speaker honoraria from Elanco, Zoetis, and Arthrex.